Progastrin-Releasing Peptide Precursor and Neuron-Specific Enolase Predict the Efficacy of First-Line Treatment with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors Among Non-Small-Cell Lung Cancer Patients Harboring EGFR Mutations-Reference-Cited by-同舟云学术

Progastrin-Releasing Peptide Precursor and Neuron-Specific Enolase Predict the Efficacy of First-Line Treatment with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors Among Non-Small-Cell Lung Cancer Patients Harboring EGFR Mutations

Published:2021-01 Issue: Volume:Volume 12 Page:13607-13616
ISSN:1179-1322
Container-title:Cancer Management and Research
language:en
Short-container-title:CMAR

Author:

Dong Juanjuan^ORCID,Tong Sihao,Shi Xianfeng,Wang Chao,Xiao Xin,Ji Wenping,Sun Yimian

Publisher

Informa UK Limited

Subject

Oncology

Reference37 articles.

1. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)

2. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

3. Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology – Mainland China Subset Analysis of the PIONEER study

4. Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis

5. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and validation of a survival prediction model for patients with advanced non-small cell lung cancer based on LASSO regression;Frontiers in Immunology;2024-08-02

2. Circulating tumor cells are a good predictor of tumor recurrence in clinical patients with gastric cancer;Scientific Reports;2024-06-04

3. Beyond ENO1, emerging roles and targeting strategies of other enolases in cancers;Molecular Therapy - Oncolytics;2023-12

4. Prognostic value of blood-based protein biomarkers in non-small cell lung cancer: A critical review and 2008–2022 update;Tumor Biology;2023-10-28

5. Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study;Targeted Oncology;2023-08-23